

Annual Safety report AID-ICU trial

EudraCT number	2017-003829-15	
Clinical Trial Title	Agents Intervening against Delirium in the Intensive Care Unit -	
Sponsor	Lone Musaeus Poulsen, MD	
Designated reporter	Nina Christine Andersen-Ranberg, MD, PhD-student	
Medicines Agency Journal number	2017-101527	
Ethics Committee case number	SJ-646	
Date of initial authorization	December 5, 2017	

Period of reporting: January 1th 2022 to December 31 2022

SAR in the period of reporting: 56 included patients, 3 SARs

SUSAR in the period of reporting: 56 patients included, 0 SUSAR

Conclusions in observed SAR/SUSAR:

One case of Ventricular Tachycardia (VT) has been reported among trial participants in 2022. The patient that experienced VT were discontinued from trial medication and treated according to local guidelines. One case of extrapyramidal symptoms has been reported among trial participants in 2022. Trial medication was discontinued and symptoms resolved after a few days. One patient experienced tardive dyskinesia, patient was treated with akineton and symptoms resolve.

Benefit-risk evaluation

Based on the above reported, the risk and benefits for the patients are considered unchanged.

Implication for the clinical trial population:			
Change in/ amendment to protocol	□ yes	⊠ no	
Change in study procedures	□ yes	⊠ no	
Change in patient information	□ yes	⊠ no	
Change in informed consent form	□ yes	⊠ no	
Date: 19/1 - 23	Signature:	Paux	

